Cargando…

The Association between Proton Pump Inhibitors and the Effectiveness of CDK Inhibitors in HR+/HER- Advanced Breast Cancer Patients: A Systematic Review and Meta-Analysis

SIMPLE SUMMARY: Proton pump inhibitors (PPIs) are frequently used in many patients with advanced breast cancer who are being treated with cyclin-dependent kinase inhibitors. In this study, our aim was to determine if there is an association between the use of PPIs and the effectiveness of cyclin-dep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Yu-Cheng, Song, Junmin, Chang, Yu, Huang, Chin-Hsuan, Sudan, Aarushi, Chen, Pei-Chin, Chi, Kuan-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649865/ https://www.ncbi.nlm.nih.gov/pubmed/37958308 http://dx.doi.org/10.3390/cancers15215133

Ejemplares similares

The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis
por: Chang, Yu, et al.
Publicado: (2022)

Proton Pump Inhibitor Use and Risk of Gastric Cancer: Current Evidence from Epidemiological Studies and Critical Appraisal
por: Poly, Tahmina Nasrin, et al.
Publicado: (2022)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Do proton pump inhibitors affect the effectiveness of chemotherapy in colorectal cancer patients? A systematic review with meta-analysis
por: Lin, Wan-Ying, et al.
Publicado: (2022)

Proton pump inhibitors and colorectal cancer: A systematic review
por: Patel, Agastya, et al.
Publicado: (2021)

HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
por: Sammons, Sarah L., et al.
Publicado: (2017)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
por: Zattarin, Emma, et al.
Publicado: (2023)

Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer
por: Zhao, Joseph J., et al.
Publicado: (2023)

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
por: Di Cosimo, Serena, et al.
Publicado: (2020)

The Use of Proton Pump Inhibitors and COVID-19: A Systematic Review and Meta-Analysis
por: Fatima, Kaneez, et al.
Publicado: (2022)

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
por: Rossi, Lorenzo, et al.
Publicado: (2018)

Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer
por: Zhang, Jian, et al.
Publicado: (2021)

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
por: Cogliati, Viola, et al.
Publicado: (2022)

Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2− Advanced Breast Cancer
por: Xie, Ning, et al.
Publicado: (2020)

Proton pump inhibitor use increases hepatic encephalopathy risk: A systematic review and meta-analysis
por: Ma, Yun-Jie, et al.
Publicado: (2019)

Paradoxical relationship between proton pump inhibitors and COVID-19: A systematic review and meta-analysis
por: Zippi, Maddalena, et al.
Publicado: (2021)

Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
por: Dong, Brian, et al.
Publicado: (2023)

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center
por: Knudsen, Erik S, et al.
Publicado: (2022)

Investigation of the interaction between proton pump inhibitors and clopidogrel using VerifyNow P2Y12 assay
por: Lin, Sheng-Feng, et al.
Publicado: (2020)

Proton Pump Inhibitors Increase the Risk of Autoimmune Diseases: A Nationwide Cohort Study
por: Lin, Sheng-Hong, et al.
Publicado: (2021)

The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Long-Term Usage of Proton Pump Inhibitors Associated with Prognosis in Patients with Colorectal Cancer
por: Wu, Chin-Chia, et al.
Publicado: (2023)

The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry
por: Meegdes, Marissa, et al.
Publicado: (2021)

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
por: D’Angelo, Alberto, et al.
Publicado: (2022)

The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis
por: Ding, Wu, et al.
Publicado: (2018)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Proton pump inhibitors and risk of periampullary cancers—A nested case–control study
por: Chien, Li‐Nien, et al.
Publicado: (2015)

Gastrointestinal symptoms associated with gastroesophageal reflux disease, and their relapses after treatment with proton pump inhibitors: A systematic review
por: Hosseini, Mousalreza, et al.
Publicado: (2017)

Proton Pump Inhibitors and Gastritis
por: Suzuki, Masayuki, et al.
Publicado: (2008)

Proton pump inhibitors and gastroenteritis
por: Hassing, Robert-Jan, et al.
Publicado: (2016)

Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023)

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
por: Stanciu, Ioana-Miruna, et al.
Publicado: (2023)

The Perilous PPI: Proton Pump Inhibitor as a Cause of Clinically Significant Hypomagnesaemia
por: Tai, Yong Ting, et al.
Publicado: (2020)

Cellular senescence in the response of HR(+) breast cancer to radiotherapy and CDK4/6 inhibitors
por: Klapp, Vanessa, et al.
Publicado: (2023)

Long-term Proton Pump Inhibitor Administration Caused Physiological and Microbiota Changes in Rats
por: Yang, Yu-Chen S. H., et al.
Publicado: (2020)

Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan
por: Tai, Shu-Yu, et al.
Publicado: (2017)

Impact of perioperative α1-antagonists on postoperative urinary retention in orthopaedic surgery: meta-analysis
por: Huang, Yun-Ting, et al.
Publicado: (2023)

Immune effects of CDK4/6 inhibitors in patients with HR(+)/HER2(−) metastatic breast cancer: Relief from immunosuppression is associated with clinical response
por: Scirocchi, Fabio, et al.
Publicado: (2022)

Proton-pump inhibitor use amongst patients with severe hypomagnesemia
por: Seah, Sherry, et al.
Publicado: (2023)

CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis
por: Zeng, Ni, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f84fgt2ni15tk79k8cts8mtj4t